Investment Analysts’ Recent Ratings Changes for Ultragenyx Pharmaceutical (RARE)

A number of research firms have changed their ratings and price targets for Ultragenyx Pharmaceutical (NASDAQ: RARE):

• 10/6/2026 – Ultragenyx Pharmaceutical had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/23/2026 – Ultragenyx Pharmaceutical was upgraded by William Blair to “hold”.
• 9/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Barclays PLC from $32.00 to $35.00. They now have an “overweight” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $18.00 to $20.00. They now have an “equal weight” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup Inc. from $31.00 to $32.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $37.00 to $39.00. They now have a “buy” rating on the stock.
• 9/18/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $33.00 to $39.00. They now have an “overweight” rating on the stock.
• 9/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $19.00. They now have a “neutral” rating on the stock.
• 9/4/2026 – Ultragenyx Pharmaceutical had its price target lowered by Barclays PLC from $43.00 to $32.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Royal Bank Of Canada from “moderate buy” to “hold”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Jefferies Financial Group Inc. from $77.00 to $28.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Citigroup Inc. from $58.00 to $28.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by TD Cowen from $49.00 to $18.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Bank of America Corporation from “buy” to “neutral”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Wedbush from $30.00 to $23.00. They now have a “neutral” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Canaccord Genuity Group Inc. from $83.00 to $37.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by William Blair from “outperform” to “market perform”.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by Cantor Fitzgerald from $103.00 to $33.00. They now have an “overweight” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical had its price target lowered by HC Wainwright from $50.00 to $25.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Evercore Inc from “outperform” to “in-line”. They now have a $16.00 price target on the stock.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Robert W. Baird from “outperform” to “neutral”. They now have a $16.00 price target on the stock, down from $40.00.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by JPMorgan Chase & Co. from “overweight” to “neutral”. They now have a $36.00 price target on the stock, down from $80.00.
• 9/3/2026 – Ultragenyx Pharmaceutical was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $18.00 price target on the stock, down from $50.00.
• 8/28/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $46.00 to $50.00. They now have an “overweight” rating on the stock.
• 8/25/2026 – Ultragenyx Pharmaceutical had its price target raised by JPMorgan Chase & Co. from $75.00 to $80.00. They now have an “overweight” rating on the stock.
• 8/21/2026 – Ultragenyx Pharmaceutical had its price target raised by Morgan Stanley from $67.00 to $74.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Canaccord Genuity Group Inc. from $81.00 to $83.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Citigroup Inc. from $45.00 to $58.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Wells Fargo & Company from $45.00 to $46.00. They now have an “overweight” rating on the stock.
• 8/20/2026 – Ultragenyx Pharmaceutical had its price target raised by Cantor Fitzgerald from $96.00 to $103.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Ultragenyx Pharmaceutical had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII.